Search

Displaying results 4391 - 4400 of 8010 in total
  1. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse. … It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk

  2. Drug

    Isoxaflutole

    go.drugbank.com/drugs/DB12938
    ApprovedWithdrawn

    Balance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.

  3. Drug

    Coccidioides immitis spherule

    go.drugbank.com/drugs/DB11294
    Approved

    Coccidioides immitis spherule is a skin test antigen indicated to detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.

  4. Drug

    Nitrazepam

    go.drugbank.com/drugs/DB01595
    Approved

    A benzodiazepine derivative used as an anticonvulsant and hypnotic.

  5. Drug

    Zytron

    go.drugbank.com/drugs/DB11768
    ApprovedWithdrawn

    DMPA has been investigated for the prevention, treatment, and basic science of Weight and Microbiota. … Zytron (DMPA) is under investigation for the treatment and health services research of HIV, Lactation, Contraception, Postpartum Depression, and Immune Cells (Mucosal and Systemic).

  6. Drug

    Enpatoran

    go.drugbank.com/drugs/DB16501
    Investigational

    Enpatoran (M5049) was under investigation in clinical trials for various conditions. … Additionally, M5049 was studied for COVID-19 pneumonia in a completed trial with results (NCT04448756) and is currently being recruited for a trial involving participants with dermatomyositis and polymyositis

    Categories: Experimental Unapproved Treatments for COVID-19
  7. Drug

    Veru-111

    go.drugbank.com/drugs/DB16462
    Investigational

    VERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360.

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    Dactylis glomerata pollen

    go.drugbank.com/drugs/DB10379
    Approved

    Dactylis glomerata pollen is the pollen of the Dactylis glomerata plant. Dactylis glomerata pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Four Standardized Grasses, K-O-T Standardized Grass Pollen Mix
  9. Drug

    Poa pratensis pollen

    go.drugbank.com/drugs/DB10366
    Approved

    Poa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Four Standardized Grasses, K-O-T Standardized Grass Pollen Mix
  10. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion … of patients with idiopathic myelofibrosis or essential thrombocythemia.